Meeting
2017 ASCO Annual Meeting
Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.
Presenter
Javier Martin Broto, MD, PhD
Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT02066285
Citation
J Clin Oncol 35, 2017 (suppl; abstr 11003)
DOI
10.1200/JCO.2017.35.15_suppl.11003
Abstract #
11003
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2022 ASCO Annual Meeting
Phase II trial of palbociclib in advanced sarcoma overexpressing CDK4 gene excluding dedifferentiated liposarcoma (DD LPS): A study from the Spanish Group for Research on Sarcoma (GEIS).
Speaker: Javier Martin Broto, MD, PhD,
Videos & Slides
2021 ASCO Annual Meeting
Inflammatory indexes neutrophils/lymphocytes, platelets/lymphocytes and red-cell distribution width (RDW) as prognostic biomarkers in advanced solitary fibrous tumors (SFT) treated with pazopanib: Correlative study of GEIS-32 trial.
Speaker: Javier Martin Broto, MD, PhD
Videos & Slides
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
Speaker: Makoto Endo, MD, PhD